How Clinical Trial Analysis Turns Data Into Evidence

Clinical trial analysis is the set of statistical and methodological decisions that turn raw patient data into a verdict on whether a treatment works. These decisions are not neutral bookkeeping. Which patients get counted, how missing data is handled, when the data is examined, and how endpoints are defined can all shift the result toward or away from a positive finding. Understanding how these choices work gives you a much clearer sense of what a trial’s headline number actually means and where the conclusions might be fragile.

Who Gets Counted in the Final Result

One of the first analytical decisions in any trial is which participants to include in the results. The two main approaches are intention-to-treat (ITT) analysis and per-protocol (PP) analysis. In ITT, every person randomized into the trial is counted in the group they were assigned to, regardless of whether they actually finished the treatment, took every dose, or switched to something else partway through. In PP, only those who followed the study plan as designed are included. ITT measures the real-world effect of assigning a drug, while PP measures the effect of actually receiving the treatment as specified.¹

ITT is generally considered the more conservative and reliable approach because it preserves the integrity of randomization. If you start dropping people who did not complete therapy, you risk introducing exactly the kind of bias the trial was designed to prevent. The patients who drop out are often systematically different from those who stay, and their removal can tilt the results. Per-protocol results are still commonly reported alongside ITT, but they come with a warning: comparing outcomes only among people who stuck with treatment creates what researchers call treatment-confounder feedback loops, where past health problems affect future treatment, and current treatment affects future health problems. That makes the per-protocol result harder to interpret as a clean causal estimate.²

A newer way of thinking about this problem is the estimand framework, which was formalized in the ICH E9 addendum that now guides regulatory submissions. Rather than defaulting to ITT or PP, researchers are expected to define upfront exactly what question they are trying to answer, including how to handle “intercurrent events” like a patient switching medications or needing rescue therapy. These events used to be handled silently or inconsistently. Now, analysts must specify a strategy for each one, such as whether to treat the event as if it never happened or to include whatever outcome followed it.³ This framework has improved the alignment between a trial’s clinical question and its statistical analysis, particularly in non-inferiority trials where the old ITT-versus-PP distinction was especially awkward.⁴

Bias Protection Built Into the Design

Randomization is the backbone of trial credibility, but simply randomizing is not enough. If the people enrolling patients can guess which treatment the next person will receive, they can consciously or unconsciously steer certain patients toward a preferred group. That is selection bias, and it can subvert even a properly randomized trial. A review of randomized trials found that very few used techniques that fully eliminated this risk: only about 3% used simple randomization, and just 1% blinded the recruiters to the allocation.⁵ A Cochrane review on the topic found that five out of nine studies showed larger treatment effects in trials with inadequate concealment of the randomization sequence compared to trials that concealed it properly.⁶

Blinding is the other major safeguard, and its impact on results is measurable. In trials where the person judging whether a patient improved or worsened was not blinded, the treatment effects were inflated by roughly 36% on average compared to trials where that assessor was blinded.⁷ That is a substantial distortion, and it does not require anyone to be dishonest. Knowing which group a patient belongs to can subtly shape how symptoms are recorded, how borderline cases are classified, or when follow-up tests are ordered.

Choosing What to Measure

The choice of endpoint determines what the trial is actually testing. A trial measuring whether patients survive longer is answering a different question than one measuring whether a blood marker improves, even if the drug is the same. Hard endpoints like death or heart attack are unambiguous but require large trials and long follow-up periods. Softer measures like tumor shrinkage or bone density changes are faster to observe but may not reliably predict the outcome patients care about.

This is where surrogate endpoints come in. A valid surrogate is a lab measurement or imaging result that reliably predicts a clinically meaningful outcome. Validating surrogates requires showing that the treatment’s effect on the surrogate translates into an effect on the real outcome. In osteoporosis research, for example, researchers used data from over 61,000 patients across 16 trials to define how much bone mineral density at the hip needs to increase before you can reliably predict a reduction in fractures. The thresholds varied by fracture type, from about 1.4% for vertebral fractures to about 3.2% for hip fractures, and the approach was confirmed in a separate set of trials not used to develop it.⁸

Many trials use composite endpoints, bundling several outcomes into a single measure. A cardiology trial might combine death, heart attack, and hospitalization for heart failure into one composite. The statistical method matters here. Traditional time-to-first-event analysis counts only the first bad thing that happens to each patient, which throws away information. Methods that count all events for each patient tend to have more statistical power.⁹ A newer approach called the win ratio ranks the components in a hierarchy, with death at the top. In this method, the highest-ranked component dominates the power calculation, especially when it has both a large treatment effect and a high event rate. Adding a continuous measure like walking distance to the composite, even with a small treatment effect, can dramatically increase statistical power.¹⁰

Looking at the Data Before the Trial Ends

Most large trials do not wait until every patient has finished to start analyzing. Interim analyses let researchers, usually through an independent monitoring board, peek at accumulating data to check whether the treatment is clearly working, clearly failing, or causing unexpected harm. The catch is that each peek raises the chance of a false positive. If you test for a difference five times during a trial instead of once at the end, you are more likely to find a spurious one purely by chance.

The standard solution is alpha spending, where the total acceptable false-positive risk for the trial is budgeted across all planned looks at the data. The threshold for declaring superiority at each interim analysis is set much higher than it would be at the final analysis, so that the overall false-positive rate stays at the planned level. Alpha spending functions allow flexibility in when the interim looks happen without compromising the statistical validity of the final result.¹¹¹²

Adaptive designs take this further by allowing pre-planned modifications to the trial itself based on interim data. The most common adaptation is sample size re-estimation, where the trial can be enlarged if the effect appears smaller than originally assumed. About 24% of adaptive trial protocols include this type of adjustment.¹³ The efficiency gains from these designs over simpler group sequential approaches are real but modest in realistic settings.¹⁴

The Problem of Missing Data

Patients drop out of trials for all kinds of reasons: side effects, loss of interest, moving away, getting better and seeing no need to continue, or getting worse and seeking different care. The reasons matter enormously. If dropout is essentially random, the remaining data can still give you a reliable picture. If patients drop out because the treatment is not working or is making them sicker, the remaining completers will look artificially good.

The recommended approach for handling missing data is multiple imputation, which fills in plausible values for each missing observation multiple times, runs the analysis on each version, and combines the results in a way that accounts for the uncertainty introduced by not knowing the true values.¹⁵ This works well when data is missing at random or completely at random, but it cannot rescue a situation where the missingness itself depends on the unobserved outcome. In the older method of last observation carried forward, a patient’s most recent measurement is simply treated as their final result, which tends to give misleading coverage and biased estimates.¹⁶

A particularly tricky scenario involves patients who provide baseline data but then have no post-baseline measurements at all. Simulations suggest that assigning these patients a change of zero at the first post-baseline visit and analyzing with baseline as a covariate controls false-positive rates and generally performs as well as or better than other approaches. Treatment comparisons remained unbiased even when the missingness was related to the treatment itself, as long as it was not simultaneously tied to the outcome.¹⁷

Subgroup Analysis and the Multiplicity Trap

After a trial reports its main result, it is tempting to slice the data into subgroups: did the drug work better in women than men? In younger patients versus older ones? In patients with severe disease versus mild? These analyses are common and can generate clinically important hypotheses, but they come with a statistical land mine: the more subgroups you test, the more likely you are to find a spuriously positive or negative result simply by chance.

Multiplicity adjustments correct for this by raising the statistical bar for each comparison when many are being tested. Without them, the selection bias inherent in searching across many subgroups makes the findings unreliable.¹⁸ In confirmatory settings, where a trial is designed from the start to test a specific subgroup alongside the full population, there are established methods for splitting the statistical budget across populations so that each finding can stand on its own.¹⁹ When you read that a drug “worked in patients over 65 but not in younger adults,” it is worth asking whether that distinction was planned from the start or discovered after the fact. The planned version is far more credible.

Non-Inferiority Trials

Not every trial aims to prove a new treatment is better than an existing one. Non-inferiority trials ask a different question: is the new treatment at least not meaningfully worse? These arise when the new option has some other advantage, like fewer side effects, easier dosing, or lower cost, and researchers just need to confirm it does not sacrifice too much effectiveness.

The analytical challenge is defining the non-inferiority margin, which sets how much worse the new treatment can be before it is considered unacceptably inferior. There is no consensus on the best way to define this margin, and previous studies have found that the rationale for its choice is often not even reported.²⁰ The FDA-preferred fixed-margin method takes a conservative approach by basing the margin on the lower end of the confidence interval from historical trials of the active comparator, rather than on its average effect. This builds in a safety buffer but depends on the assumption that the comparator’s historical effect would hold steady in a new trial.²¹ If that assumption breaks down, the entire trial’s conclusion is in jeopardy. This makes non-inferiority trials particularly sensitive to analytical choices that might seem like technical details but actually determine the trial’s credibility.

From Individual Trials to Pooled Evidence

Individual trials are noisy. Meta-analysis pools results from multiple trials on the same question to get a more precise estimate, but even this step involves analytical choices with real consequences. The two main statistical models, fixed effects and random effects, can give different answers. A comparison of meta-analyses in perinatal medicine found that the random effects model produced wider confidence intervals, as expected, but it also tended to show larger protective treatment effects than the fixed effects model when there was substantial variation across trials.²² These opposing forces, stronger effect but less certainty, mean the choice of model can determine whether a pooled result crosses the threshold for statistical significance.

Reporting Standards and Reproducibility

The CONSORT statement is the checklist that clinical trial reports are supposed to follow, covering everything from how randomization was done to how many patients dropped out and why. Adoption of CONSORT improved reporting quality, with one study finding that unexplained attrition dropped from about 69% of total dropout before CONSORT to 13% after.²³ That said, adherence remains uneven. An assessment of trial abstracts from four major medical journals found persistent inconsistencies, especially in reporting methodological details.²⁴

Reproducibility, the ability for an independent analyst to reach the same conclusion using the same data, is a related concern. Among trials published in journals that required full data sharing, roughly half actually made their data available. Of those that did, about 82% were fully reproduced on their primary outcomes. The remainder had minor errors but reached similar conclusions, except for one trial that did not describe its methods in enough detail for anyone to replicate the analysis.²⁵ That only half of trials in data-sharing journals actually shared data highlights a gap between policy and practice.

Synthetic Control Arms and Machine Learning

Some of the most interesting developments in clinical trial analysis involve replacing or supplementing parts of the traditional trial design. Synthetic control arms draw on data from previous trials or real-world medical records to construct a comparison group, potentially eliminating the need to randomize some patients to standard care. In a study of elderly lymphoma patients over 80, a synthetic control arm built from a mix of historical trial and real-world data closely reproduced the results of the internal control arm from an actual randomized trial.²⁶ A separate study used a synthetic real-world cohort to compare the lung cancer drug pralsetinib against standard treatment, finding substantially better outcomes in the drug’s favor on survival and time-to-treatment-discontinuation measures.²⁷ These approaches are especially appealing in rare diseases or elderly populations where recruiting enough patients for a conventional control group is difficult.

Machine learning is also entering the analytical toolkit, though not in the way you might expect. Rather than replacing statistical tests, algorithms like random forests and gradient boosting are being used to adjust for baseline differences between groups more precisely than traditional linear models. Simulations show these methods can boost the statistical efficiency of a trial while still controlling false-positive rates.²⁸ A related line of work applies machine learning to adaptive randomization in multi-arm trials, updating the probability of assigning a new patient to each treatment based on how earlier patients responded, while adjusting for individual patient characteristics.²⁹ These methods do not require the machine learning model to perfectly capture the true relationship between patient characteristics and outcomes; they just need to converge to something stable enough to improve precision.³⁰

Regulatory Shifts in What Counts as Proof

For decades, the gold standard for drug approval at the FDA was two independent pivotal trials showing the same result. The logic was straightforward: if two separate experiments agree, the finding is probably real. Recently, the FDA moved toward accepting a single pivotal trial as the default evidentiary standard, a shift from replication-based validation to what has been described as a coherence-based model, where one well-designed trial with strong internal consistency can be sufficient.³¹ This change reflects the practical reality that many drugs target small patient populations where running two full-scale trials is neither feasible nor ethical, but it also places more weight on the quality of analysis within that single trial. Every analytical decision described in this article, from how endpoints are chosen to how missing data is handled, matters more when there is no second trial to catch what the first one got wrong.